Androgen replacement in adolescents and young women with hypopituitarism

Marie Bilger, Susan Speraw, Stephen Lafranchi, Cheryl Hanna

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The aim of this study was to test the hypothesis that young women with androgen deficiency due to hypopituitarism would benefit from androgen replacement in the form of dehydroepiandrosterone (DHEA). Five young women, age 15.2-23.1 years, with panhypopituitarism were studied in a 12-month double blind placebo-controlled crossover trial of DHEA replacement in a dose 50 mg/day (Belmar Pharmacy, Lakewood, CO). All had growth hormone (GH), thyroid stimulating hormone (TSH), adrenocorticotropic hormone (ACTH) and antidiuretic hormone deficiencies. Gonadotropin deficiency was complete in three and partial in two. The patients were evaluated at baseline, 6 months and 12 months. Serum hormone levels, body composition, lumbar bone mineral density (BMD), exercise capacity and tests of psychological function were performed. DHEA replacement restored serum DHEA levels to normal, 359.8 ± 337 ng/dl (12.5 ± 11.7 nmol/l). The Life Situation Survey showed significantly better life satisfaction on DHEA than placebo (110 vs 102, p = 0.05). Trends for improved maximal oxygen uptake (VO2), and decreased percent body fat did not reach statistical significance. In conclusion, androgen replacement with DHEA should be considered in young women with panhypopituitarism. Further studies over longer periods in larger groups of patients are necessary to better evaluate the effects of DHEA replacement on BMD, muscle strength and body composition.

Original languageEnglish (US)
Pages (from-to)355-362
Number of pages8
JournalJournal of Pediatric Endocrinology and Metabolism
Volume18
Issue number4
StatePublished - Apr 2005

Fingerprint

Hypopituitarism
Dehydroepiandrosterone
Androgens
Body Composition
Bone Density
Placebos
Muscle Strength
Thyrotropin
Carbon Monoxide
Serum
Vasopressins
Gonadotropins
Exercise Test
Adrenocorticotropic Hormone
Cross-Over Studies
Growth Hormone
Adipose Tissue
Hormones
Psychology
Oxygen

Keywords

  • Adrenal insufficiency
  • Androgen deficiency
  • Dehydroepiandrosterone replacement
  • Panhypopituitarism

ASJC Scopus subject areas

  • Endocrinology
  • Pediatrics, Perinatology, and Child Health

Cite this

Androgen replacement in adolescents and young women with hypopituitarism. / Bilger, Marie; Speraw, Susan; Lafranchi, Stephen; Hanna, Cheryl.

In: Journal of Pediatric Endocrinology and Metabolism, Vol. 18, No. 4, 04.2005, p. 355-362.

Research output: Contribution to journalArticle

Bilger, M, Speraw, S, Lafranchi, S & Hanna, C 2005, 'Androgen replacement in adolescents and young women with hypopituitarism', Journal of Pediatric Endocrinology and Metabolism, vol. 18, no. 4, pp. 355-362.
Bilger, Marie ; Speraw, Susan ; Lafranchi, Stephen ; Hanna, Cheryl. / Androgen replacement in adolescents and young women with hypopituitarism. In: Journal of Pediatric Endocrinology and Metabolism. 2005 ; Vol. 18, No. 4. pp. 355-362.
@article{bd2468fc4f5c4d1d880739a149abdcbd,
title = "Androgen replacement in adolescents and young women with hypopituitarism",
abstract = "The aim of this study was to test the hypothesis that young women with androgen deficiency due to hypopituitarism would benefit from androgen replacement in the form of dehydroepiandrosterone (DHEA). Five young women, age 15.2-23.1 years, with panhypopituitarism were studied in a 12-month double blind placebo-controlled crossover trial of DHEA replacement in a dose 50 mg/day (Belmar Pharmacy, Lakewood, CO). All had growth hormone (GH), thyroid stimulating hormone (TSH), adrenocorticotropic hormone (ACTH) and antidiuretic hormone deficiencies. Gonadotropin deficiency was complete in three and partial in two. The patients were evaluated at baseline, 6 months and 12 months. Serum hormone levels, body composition, lumbar bone mineral density (BMD), exercise capacity and tests of psychological function were performed. DHEA replacement restored serum DHEA levels to normal, 359.8 ± 337 ng/dl (12.5 ± 11.7 nmol/l). The Life Situation Survey showed significantly better life satisfaction on DHEA than placebo (110 vs 102, p = 0.05). Trends for improved maximal oxygen uptake (VO2), and decreased percent body fat did not reach statistical significance. In conclusion, androgen replacement with DHEA should be considered in young women with panhypopituitarism. Further studies over longer periods in larger groups of patients are necessary to better evaluate the effects of DHEA replacement on BMD, muscle strength and body composition.",
keywords = "Adrenal insufficiency, Androgen deficiency, Dehydroepiandrosterone replacement, Panhypopituitarism",
author = "Marie Bilger and Susan Speraw and Stephen Lafranchi and Cheryl Hanna",
year = "2005",
month = "4",
language = "English (US)",
volume = "18",
pages = "355--362",
journal = "Journal of Pediatric Endocrinology and Metabolism",
issn = "0334-018X",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "4",

}

TY - JOUR

T1 - Androgen replacement in adolescents and young women with hypopituitarism

AU - Bilger, Marie

AU - Speraw, Susan

AU - Lafranchi, Stephen

AU - Hanna, Cheryl

PY - 2005/4

Y1 - 2005/4

N2 - The aim of this study was to test the hypothesis that young women with androgen deficiency due to hypopituitarism would benefit from androgen replacement in the form of dehydroepiandrosterone (DHEA). Five young women, age 15.2-23.1 years, with panhypopituitarism were studied in a 12-month double blind placebo-controlled crossover trial of DHEA replacement in a dose 50 mg/day (Belmar Pharmacy, Lakewood, CO). All had growth hormone (GH), thyroid stimulating hormone (TSH), adrenocorticotropic hormone (ACTH) and antidiuretic hormone deficiencies. Gonadotropin deficiency was complete in three and partial in two. The patients were evaluated at baseline, 6 months and 12 months. Serum hormone levels, body composition, lumbar bone mineral density (BMD), exercise capacity and tests of psychological function were performed. DHEA replacement restored serum DHEA levels to normal, 359.8 ± 337 ng/dl (12.5 ± 11.7 nmol/l). The Life Situation Survey showed significantly better life satisfaction on DHEA than placebo (110 vs 102, p = 0.05). Trends for improved maximal oxygen uptake (VO2), and decreased percent body fat did not reach statistical significance. In conclusion, androgen replacement with DHEA should be considered in young women with panhypopituitarism. Further studies over longer periods in larger groups of patients are necessary to better evaluate the effects of DHEA replacement on BMD, muscle strength and body composition.

AB - The aim of this study was to test the hypothesis that young women with androgen deficiency due to hypopituitarism would benefit from androgen replacement in the form of dehydroepiandrosterone (DHEA). Five young women, age 15.2-23.1 years, with panhypopituitarism were studied in a 12-month double blind placebo-controlled crossover trial of DHEA replacement in a dose 50 mg/day (Belmar Pharmacy, Lakewood, CO). All had growth hormone (GH), thyroid stimulating hormone (TSH), adrenocorticotropic hormone (ACTH) and antidiuretic hormone deficiencies. Gonadotropin deficiency was complete in three and partial in two. The patients were evaluated at baseline, 6 months and 12 months. Serum hormone levels, body composition, lumbar bone mineral density (BMD), exercise capacity and tests of psychological function were performed. DHEA replacement restored serum DHEA levels to normal, 359.8 ± 337 ng/dl (12.5 ± 11.7 nmol/l). The Life Situation Survey showed significantly better life satisfaction on DHEA than placebo (110 vs 102, p = 0.05). Trends for improved maximal oxygen uptake (VO2), and decreased percent body fat did not reach statistical significance. In conclusion, androgen replacement with DHEA should be considered in young women with panhypopituitarism. Further studies over longer periods in larger groups of patients are necessary to better evaluate the effects of DHEA replacement on BMD, muscle strength and body composition.

KW - Adrenal insufficiency

KW - Androgen deficiency

KW - Dehydroepiandrosterone replacement

KW - Panhypopituitarism

UR - http://www.scopus.com/inward/record.url?scp=17144402583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144402583&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 355

EP - 362

JO - Journal of Pediatric Endocrinology and Metabolism

JF - Journal of Pediatric Endocrinology and Metabolism

SN - 0334-018X

IS - 4

ER -